FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2937062829> ?p ?o ?g. }

• W2937062829 endingPage "3123" @default.
• W2937062829 startingPage "3111" @default.
• W2937062829 abstract "MicroRNA-665 inhibits the oncogenicity of retinoblastoma by directly targeting high-mobility group box 1 and inactivating the Wnt/β-catenin pathway Shuai Wang, Shanshan Du, Yong Lv, Fengyan Zhang, Wenzhan WangDepartment of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, People’s Republic of ChinaPurpose: Previous studies have revealed that microRNA-665 (miR-665) is dysregulated in a variety of human cancers. However, little is known regarding its expression profiles and functions in retinoblastoma (RB). Therefore, the aims of our study were to evaluate miR-665 expression in RB and determine the precise roles of miR-665 in the progression of RB.Patients and methods: Herein, RT-qPCR was used to determine miR-665 expression levels in RB tissues and cell lines, and a series of functional experiments were performed to explore the influence of miR-665 on RB cell proliferation, colony formation, apoptosis, migration, and invasion as well as tumor growth. The molecular mechanisms underlying the tumor-suppressive action of miR-665 in RB were also explored.Results: We found that miR-665 was markedly reduced in RB tissues and cell lines and that lower miR-665 expression was strongly associated with tumor size, TNM stage, and differentiation in patients with RB. Exogenous expression of miR-665 suppressed cell proliferation, colony formation, migration, and invasion, and induced cell apoptosis in RB cells, while silencing miR-665 expression had the opposite effects. In addition, upregulation of miR-665 decreased the tumor growth of RB cells in vivo. High-mobility group box 1 (HMGB1) was identified as a direct target of miR-665 in RB cells, and decreasing the expression of HMGB1 simulated the regulatory effects of miR-665 overexpression in RB cells, while knockdown of HMGB1 expression counteracted the miR-665-mediated antitumor effects in RB cells. Moreover, miR-665 was shown to regulate the Wnt/β-catenin signaling pathway by targeting HMGB1 in vitro and in vivo.Conclusion: Taken together, our in vitro and in vivo results suggest that miR-665 acts as a tumor-suppressive miRNA in RB by directly targeting HMGB1 and inactivating the Wnt/β-catenin pathway. Hence, this miRNA is a candidate prognostic biomarker and therapeutic target in patients with RB.Keywords: microRNA-665, retinoblastoma, high-mobility group box 1, Wnt/β-catenin pathway, oncogenicity" @default.
• W2937062829 created "2019-04-25" @default.
• W2937062829 creator A5000382949 @default.
• W2937062829 creator A5006901857 @default.
• W2937062829 creator A5017273285 @default.
• W2937062829 creator A5074936419 @default.
• W2937062829 creator A5086677187 @default.
• W2937062829 date "2019-04-01" @default.
• W2937062829 modified "2023-10-18" @default.
• W2937062829 title "<p>MicroRNA-665 inhibits the oncogenicity of retinoblastoma by directly targeting high-mobility group box 1 and inactivating the Wnt/&beta;-catenin pathway</p>" @default.
• W2937062829 cites W144423133 @default.
• W2937062829 cites W1513564715 @default.
• W2937062829 cites W1902808961 @default.
• W2937062829 cites W1989793529 @default.
• W2937062829 cites W1998751511 @default.
• W2937062829 cites W2002239479 @default.
• W2937062829 cites W2032844416 @default.
• W2937062829 cites W2059878940 @default.
• W2937062829 cites W2085047799 @default.
• W2937062829 cites W2104389740 @default.
• W2937062829 cites W2107277218 @default.
• W2937062829 cites W2120463449 @default.
• W2937062829 cites W2152364510 @default.
• W2937062829 cites W2180824931 @default.
• W2937062829 cites W2237621283 @default.
• W2937062829 cites W2550133015 @default.
• W2937062829 cites W2560236165 @default.
• W2937062829 cites W2586100275 @default.
• W2937062829 cites W2592702099 @default.
• W2937062829 cites W2597941589 @default.
• W2937062829 cites W2612273911 @default.
• W2937062829 cites W2724385814 @default.
• W2937062829 cites W2735867739 @default.
• W2937062829 cites W2751076114 @default.
• W2937062829 cites W2753935426 @default.
• W2937062829 cites W2755117699 @default.
• W2937062829 cites W2772265911 @default.
• W2937062829 cites W2783702539 @default.
• W2937062829 cites W2802030953 @default.
• W2937062829 cites W2805089662 @default.
• W2937062829 cites W2807489671 @default.
• W2937062829 cites W2807907278 @default.
• W2937062829 cites W2808548488 @default.
• W2937062829 cites W2810684953 @default.
• W2937062829 cites W284527303 @default.
• W2937062829 cites W2875404534 @default.
• W2937062829 cites W2883476372 @default.
• W2937062829 cites W2885281818 @default.
• W2937062829 cites W2887046710 @default.
• W2937062829 cites W2891433775 @default.
• W2937062829 cites W2893077384 @default.
• W2937062829 cites W2896889415 @default.
• W2937062829 cites W2900597665 @default.
• W2937062829 cites W2987260256 @default.
• W2937062829 cites W2529456977 @default.
• W2937062829 doi "https://doi.org/10.2147/cmar.s200566" @default.
• W2937062829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6489654" @default.
• W2937062829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31114354" @default.
• W2937062829 hasPublicationYear "2019" @default.
• W2937062829 type Work @default.
• W2937062829 sameAs 2937062829 @default.
• W2937062829 citedByCount "18" @default.
• W2937062829 countsByYear W29370628292019 @default.
• W2937062829 countsByYear W29370628292020 @default.
• W2937062829 countsByYear W29370628292021 @default.
• W2937062829 countsByYear W29370628292022 @default.
• W2937062829 countsByYear W29370628292023 @default.
• W2937062829 crossrefType "journal-article" @default.
• W2937062829 hasAuthorship W2937062829A5000382949 @default.
• W2937062829 hasAuthorship W2937062829A5006901857 @default.
• W2937062829 hasAuthorship W2937062829A5017273285 @default.
• W2937062829 hasAuthorship W2937062829A5074936419 @default.
• W2937062829 hasAuthorship W2937062829A5086677187 @default.
• W2937062829 hasBestOaLocation W29370628291 @default.
• W2937062829 hasConcept C104317684 @default.
• W2937062829 hasConcept C119056186 @default.
• W2937062829 hasConcept C127561419 @default.
• W2937062829 hasConcept C137620995 @default.
• W2937062829 hasConcept C145059251 @default.
• W2937062829 hasConcept C185592680 @default.
• W2937062829 hasConcept C190283241 @default.
• W2937062829 hasConcept C2776577112 @default.
• W2937062829 hasConcept C502942594 @default.
• W2937062829 hasConcept C55493867 @default.
• W2937062829 hasConcept C62112901 @default.
• W2937062829 hasConcept C62478195 @default.
• W2937062829 hasConcept C86803240 @default.
• W2937062829 hasConceptScore W2937062829C104317684 @default.
• W2937062829 hasConceptScore W2937062829C119056186 @default.
• W2937062829 hasConceptScore W2937062829C127561419 @default.
• W2937062829 hasConceptScore W2937062829C137620995 @default.
• W2937062829 hasConceptScore W2937062829C145059251 @default.
• W2937062829 hasConceptScore W2937062829C185592680 @default.
• W2937062829 hasConceptScore W2937062829C190283241 @default.
• W2937062829 hasConceptScore W2937062829C2776577112 @default.
• W2937062829 hasConceptScore W2937062829C502942594 @default.
• W2937062829 hasConceptScore W2937062829C55493867 @default.
• W2937062829 hasConceptScore W2937062829C62112901 @default.

• next